Andrew Sinclair - Jan 28, 2022 Form 4 Insider Report for Sierra Oncology, Inc. (SRRA)

Role: Director
Signature: /s/ John Heard, as attorney-in-fact
Stock symbol: SRRA
Transactions as of: Jan 28, 2022
Transactions value $: $7,844,617
Form type: 4
Date filed: 2/1/2022, 04:04 PM
Previous filing: Dec 13, 2021
Next filing: Mar 31, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SRRA	Common Stock, $0.001 par value	Exercise of in-the-money or at-the-money derivative security	$3.79M	+287K	+32.79%	$13.20	1.16M	Jan 28, 2022	See footnotes	F1, F2
transaction	SRRA	Common Stock, $0.001 par value	Purchase	$4.05M	+150K	+12.89%	$27.00	1.31M	Jan 31, 2022	See footnotes	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SRRA	Series B Warrants (right to buy)	Exercise of in-the-money or at-the-money derivative security	$0	-287K	-100%	$0.00^*	0	Jan 28, 2022	Common Stock	287K	$13.20	See footnotes	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP.
F2	An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
F3	Each Series B warrant will expire on the 75th day anniversary of the Issuer's announcement of top-line data from its MOMENTUM Phase 3 clinical trial of momelotinib.